Inspire Medical Systems (NYSE:INSP) Price Target Lowered to $70.00 at Truist Financial

Inspire Medical Systems (NYSE:INSP) had its price target lowered by Truist Financial from $96.00 to $70.00 in a research note published on Thursday,Benzinga reports. Truist Financial currently has a hold rating on the stock.

Several other analysts also recently weighed in on INSP. Robert W. Baird set a $74.00 price objective on Inspire Medical Systems and gave the company a “neutral” rating in a research report on Thursday. Morgan Stanley reissued an “equal weight” rating and set a $130.00 price objective (up from $105.00) on shares of Inspire Medical Systems in a research report on Tuesday, December 2nd. Piper Sandler reduced their price target on Inspire Medical Systems from $165.00 to $85.00 and set an “overweight” rating on the stock in a research note on Thursday. Royal Bank Of Canada cut shares of Inspire Medical Systems from an “outperform” rating to a “sector perform” rating and cut their price objective for the stock from $175.00 to $90.00 in a report on Tuesday, January 27th. Finally, Wells Fargo & Company set a $70.00 target price on Inspire Medical Systems and gave the stock an “equal weight” rating in a research note on Thursday. Six research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $110.65.

Inspire Medical Systems Trading Down 12.4%

Shares of NYSE INSP opened at $59.74 on Thursday. Inspire Medical Systems has a 12 month low of $53.11 and a 12 month high of $197.75. The firm has a market capitalization of $1.74 billion, a price-to-earnings ratio of 12.00, a PEG ratio of 6.88 and a beta of 0.74. The business has a 50-day moving average of $94.42 and a 200-day moving average of $91.48.

Inspire Medical Systems (NYSE:INSP) last posted its quarterly earnings data on Wednesday, February 11th. The company reported $1.65 earnings per share for the quarter, beating the consensus estimate of $0.69 by $0.96. Inspire Medical Systems had a net margin of 15.95% and a return on equity of 11.47%. The firm had revenue of $269.08 million for the quarter, compared to analysts’ expectations of $264.02 million. During the same quarter last year, the company posted $1.15 EPS. The business’s quarterly revenue was up 12.2% on a year-over-year basis. On average, analysts predict that Inspire Medical Systems will post 2.16 earnings per share for the current year.

Insider Transactions at Inspire Medical Systems

In other Inspire Medical Systems news, Director Shawn Mccormick sold 2,000 shares of the company’s stock in a transaction that occurred on Friday, November 28th. The shares were sold at an average price of $127.48, for a total transaction of $254,960.00. Following the completion of the sale, the director directly owned 26,046 shares of the company’s stock, valued at approximately $3,320,344.08. This represents a 7.13% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 4.10% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. CWM LLC lifted its stake in shares of Inspire Medical Systems by 216.1% during the 4th quarter. CWM LLC now owns 354 shares of the company’s stock valued at $33,000 after buying an additional 242 shares in the last quarter. Havemeyer Place LP bought a new stake in shares of Inspire Medical Systems in the fourth quarter worth about $39,000. V Square Quantitative Management LLC purchased a new stake in Inspire Medical Systems during the fourth quarter valued at $40,000. Manning & Napier Advisors LLC bought a new stake in Inspire Medical Systems during the third quarter worth approximately $32,000. Finally, Daiwa Securities Group Inc. increased its position in Inspire Medical Systems by 38.7% during the second quarter. Daiwa Securities Group Inc. now owns 466 shares of the company’s stock valued at $60,000 after acquiring an additional 130 shares during the last quarter. 94.91% of the stock is currently owned by institutional investors.

Key Stories Impacting Inspire Medical Systems

Here are the key news stories impacting Inspire Medical Systems this week:

• Positive Sentiment: Q4 results beat and operational strength — Inspire posted $269.1M in Q4 revenue (↑12% y/y) and adjusted EPS of $1.65, topping estimates; gross margin expanded and operating cash flow and buybacks support cash returns. Earnings Release
• Neutral Sentiment: Full earnings package and call are available for deeper read — slide deck and transcript provide detail on assumptions behind the 2026 outlook and tax/adjustment impacts for modeling. Slide Deck / Press Release Call Transcript
• Negative Sentiment: Guidance cut and coding/reimbursement uncertainty — management narrowed FY2026 revenue to $950M–$1.0B and said the Inspire V procedure will likely transition to CPT 64582 with a -52 modifier, potentially lowering physician reimbursement and pressuring procedure volumes. That guidance revision is the primary driver of the selloff. MSN: Revenue Outlook & Coding
• Negative Sentiment: Immediate market reaction — analysts and headlines highlighted the coding/guidance risk and shares fell sharply despite the beat. Zacks: Stock Falls Despite Q4 Beat Investing.com: Shares Slide
• Negative Sentiment: Analyst price-target resets — multiple firms lowered targets (Jefferies to $66, Truist to $70, Mizuho to $85, Piper Sandler to $85) which increases near-term downside pressure even when some ratings remain constructive. Benzinga: Analyst Actions The Fly: Mizuho PT Cut
• Negative Sentiment: Bearish analysis and investor concerns — independent commentary highlights lingering risks around reimbursement, growth cadence and margin sustainability, reinforcing the negative sentiment. Seeking Alpha: Critical Take

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.